JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M111507200 on February 4, 2002

J. Biol. Chem., Vol. 277, Issue 16, 13787-13795, April 19, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/16/13787    most recent
M111507200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bond, M.
Right arrow Articles by Baker, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bond, M.
Right arrow Articles by Baker, A. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Tissue Inhibitor of Metalloproteinase-3 Induces a Fas-associated Death Domain-dependent Type II Apoptotic Pathway*

Mark BondDagger §, Gillian Murphy||, Martin R. Bennett**, Andrew C. NewbyDagger , and Andrew H. BakerDagger Dagger

From the Dagger  Bristol Heart Institute, Level 7, Bristol Royal Infirmary, University of Bristol, Bristol BS2 8HW, the  School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, the ** Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 2QQ, and the Dagger Dagger  Department of Medicine and Therapeutics, University of Glasgow, Glasgow G11 6NT, United Kingdom

Received for publication, December 3, 2001, and in revised form, January 29, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Tissue inhibitors of metalloproteinases (TIMPs) are important regulators of matrix metalloproteinase (MMP) and adamalysin metalloproteinase activity. We previously reported that overexpression of TIMP-3 inhibits MMPs and induces apoptotic cell death in a variety of cell types and demonstrated that apoptosis is mediated through the N terminus of TIMP-3, which harbors the MMP inhibitory domain. However, little is known about the mechanisms underlying TIMP-3-induced apoptosis. Here we demonstrate that overexpression of TIMP-3 induced activation of initiator caspase-8 and -9 and promoted caspase-mediated cleavage of the death substrates poly(ADP-ribose) polymerase and focal adhesion kinase. Furthermore, TIMP-3 induced mitochondrial activation as demonstrated by loss of mitochondrial membrane potential and release of cytochrome c. Intervention studies demonstrated that overexpression of Bcl-2, the anti-apoptotic mitochondrial membrane protein, or CrmA, a viral serpin inhibitor of caspase-8, completely inhibited TIMP-3-induced apoptosis. Furthermore, a dominant-negative Fas-associated death domain mutant inhibited TIMP-3-induced death substrate cleavage and apoptotic death. Taken together, these results indicate that TIMP-3 overexpression induces a type II apoptotic pathway initiated via a Fas-associated death domain-dependent mechanism.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Tissue inhibitors of metalloproteinases (TIMPs)1 are a family of four secreted proteins that collectively regulate the activity of the matrix metalloproteinases (MMPs) and at least some of the adamalysin proteases (1, 2). TIMPs are thought to fold into a similar two-domain structure, with each domain folded into three loops constrained by three disulfide bonds (3-6). The N-terminal domain contains a highly conserved CXC motif deemed responsible for MMP inhibition, whereas the smaller C-terminal domain confers specific functions such as the ability of TIMP-1 to interact with pro-MMP-9 and of TIMP-2 to interact with pro-MMP-2 (7-13).

TIMPs regulate MMP activity. Thus, TIMPs play important roles in regulating cellular functions that are dependent on matrix composition such as invasion, migration, differentiation, and proliferation. Several additional functions have also been attributed to individual TIMPs such as regulation of angiogenesis, activation of pro-MMP-2, and mitogenesis (14-18).

Using adenovirus-mediated gene transfer, we recently demonstrated that overexpression of TIMP-3 in human vascular smooth muscle cells and cancer cell cultures reduces cell migration and promotes apoptotic cell death, the latter being evoked through an unknown mechanism (19, 20). Furthermore, this unique phenotype induced by TIMP-3 translates to a beneficial reduction in vascular neointima formation in a human model of late vein graft failure (21). The pro-death domain of TIMP-3 has recently been localized to the N terminus, the region associated with MMP inhibitory activity (22); and it has been proposed, at least in colon cancer lines, that TIMP-3 promotes death through stabilization of tumor necrosis factor-alpha (TNF-alpha ) receptors on the cell surface, leading to increased susceptibility to apoptosis (23). Interestingly, deficiency of TIMP-3 in homozygous knockout mice results in enhanced apoptosis during mammary gland involution (24), suggesting that the physiological levels of TIMP-3 play an important role in regulating apoptosis during a number of physiological and pathological processes. It is therefore important to define the mechanism(s) through which TIMP-3 regulates apoptotic mediators when overexpressed.

Apoptotic cell death can be induced by a variety of stimuli, including death ligands such as TNF-alpha , Fas ligand, and TRAIL; DNA-damaging agents; and loss of matrix attachment in adherence-dependent cells. Many of these stimuli activate the apoptotic cascade through the action of two distinct initiator caspases, caspase-8 and -9. Caspase-9 is an important regulator of downstream effector caspases (caspase-3, -6, and -7) in response to signals generated by the mitochondria (25, 26). Its activation requires the formation of a cytosolic complex with apoptosis protease activating factor, ATP, and cytochrome c released from the mitochondria (26). Caspase-8 is typically recruited to activated death receptors via interactions with adaptor proteins such as FADD, where they form part of the death-inducing signaling complex (27). Two caspase-8-initiated apoptotic signaling pathways have been described (28). A strong activation of caspase-8 in response to death receptor activation can directly activate downstream effector caspases (type I pathway), whereas a weaker activation of caspase-8 can initiate mitochondrial activation, resulting in mitochondrial membrane depolarization, release of cytochrome c into the cytosol, and subsequent activation of caspase-9 and effector caspases (type II pathway) (28). During a type II pathway, the mitochondria act as amplifiers, resulting in additional caspase-8 activation (28).

Here we investigated the cellular mechanism activated by overexpression of TIMP-3 in primary cultures of both vascular smooth muscle cells (VSMCs) and a HeLa carcinoma cell line. We show that TIMP-3 induces a FADD-dependent type II apoptotic signaling pathway.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials

Human embryonic kidney 293 cells were purchased from Microbix (Toronto, Canada), and HeLa cells were from the European Collection of Animal Cell Cultures (Salisbury, United Kingdom). All chemicals were purchased from Sigma (Poole, UK) and were of the highest quality available. Culture media and additives were obtained from Invitrogen (Paisley, Scotland). Rabbit anti-human TIMP-3 polyclonal antibody was purchase from Chemicon International, Inc. (Harrow, UK). Recombinant human TNF-alpha and rabbit anti-cleaved poly(ADP-ribose) polymerase (PARP) (p85) antibody were purchased from Roche Molecular Biochemicals (Lewes, UK). Anti-CrmA, anti-Bcl-2, anti-focal adhesion kinase (FAK), and anti-cytochrome c antibodies and caspase substrates and inhibitors were obtained from CN Biosciences (Nottingham, UK). Anti-TNF-alpha antibody was purchased from R & D Systems. MitoTracker® Orange CMTMRos was obtained from Molecular Probes, Inc. (Leiden, The Netherlands).

Methods

Cell Culture-- Human embryonic kidney 293 cells were maintained in minimal essential medium supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin, and 10% (v/v) fetal calf serum. Rat smooth muscle cells (SMCs) were prepared from thoracic aortas as described previously (29). Rat SMCs and HeLa cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal calf serum, 100 units/ml penicillin, and 100 µg/ml streptomycin. All cells were maintained at 37 °C in an atmosphere of 95% air and 5% carbon dioxide.

Adenoviral Constructs-- The adenoviral construct rAd/TIMP-3 has been described previously (30). The control adenoviral construct rAd/beta -galactosidase was a gift from Dr. G. W. G. Wilkinson (University of Wales College of Medicine, Heath Park, Cardiff, UK). rAd/DN-FADD was a gift from Dr. C. Trautwein (Department of Gastroenterology and Hepatology, Mediziniche Hochschule Hannover, Hannover, Germany). The rAd/CrmA adenoviral construct was a gift from Dr. G. Nabel, and the rAd/Bcl-2 adenoviral construct was a gift from Dr. J. Uney.

Adenoviral Infection-- Primary rat aortic SMCs (passages 2-4) and HeLa cells were cultured in six-well plates or on sterile glass coverslips until 80% confluent. An accurate cell number was determined pre-infection by trypsinization of three wells and counting using a Neubauer hemocytometer. The remaining wells were infected at 300 (rat SMCs) and 100 (HeLa cells) plaque-forming units (pfu)/cell in 1 ml of fresh complete medium for 2 h. The medium was then replaced with 2 ml of fresh complete medium and left for the required length of time prior to analysis. For adenoviral co-infections, cells were pre-infected with either the control adenovirus or the test adenovirus at 50 pfu/cell for 2 h. Cells were then incubated in growth medium for an additional 2 h and subsequently infected with the second adenovirus at 100 pfu/cell for an additional 2 h, after which the medium was replaced with fresh complete medium.

Western Blotting-- Total cell lysates were prepared in SDS lysis buffer (50 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, and 1× Complete protease inhibitor mixture (Roche Molecular Biochemicals)). Protein concentration was determined using a Bio-Rad micro-BCA protein assay according to the manufacturer's instructions. Proteins (150 µg) were separated by SDS-PAGE under reducing conditions and transferred to Bio-Rad polyvinylidene difluoride nylon membranes. Membranes were blocked in Tris-buffered saline/Tween (200 mM Tris-HCl (pH 7.4), 137 mM NaCl, and 0.2% Tween 20) containing 5% skim milk powder, followed by incubation with primary antibody. Following washing with Tris-buffered saline/Tween, blots were incubated with horseradish peroxidase-conjugated secondary antibody for 60 min, and immunoreactive proteins were visualized using the enhanced chemiluminescence system (ECL, Amersham Biosciences).

In Situ End Labeling of DNA-- Cells were grown on glass coverslips and fixed in ice-cold methanol 72 h post-infection. After air drying, cells were washed twice with 1× TE buffer (10 mM Tris-HCl (pH 8.0) and 1 mM EDTA) and incubated in labeling mixture (50 mM Tris-HCl (pH 7.2), 10 mM MgSO4, 0.1 mM dithiothreitol, 0.01 mM dATP, 0.01 mM dCTP, 0.01 mM dGTP, 0.01 mM biotin-dUTP, and 8 units/ml DNA polymerase I (Klenow)) for 15 min at room temperature. Cells were rinsed in 1× TE buffer, and endogenous peroxidase activity was reduced by incubation in 2% H2O2 for 5 min. After further washing, biotin was labeled with ExtrAvidinTM-peroxidase conjugate (1:200). Incubation with diaminobenzidine and subsequent counterstaining with hematoxylin were carried out to distinguish between positive apoptotic nuclei containing nicked DNA and non-apoptotic nuclei.

Cell Death Enzyme-linked Immunosorbent Assay-- Apoptotic cell death was quantified using a photometric enzyme-linked immunosorbent assay for the detection of cytoplasmic histo-associated DNA fragments (Roche Molecular Biochemicals). Briefly, cell lysates were incubated with a biotin-conjugated anti-histone antibody and a peroxidase-conjugated anti-DNA antibody for 2 h. Complexes were captured on streptavidin-coated microtiter plates and quantified using ABTS colorimetric substrate.

Measurement of Mitochondrial Membrane Potential-- Mitochondrial membrane potential (Psi m) was measured using the MitoTracker® Orange CMTMRos fluorescent dye (31). Briefly, cells were incubated with MitoTracker® Orange CMTMRos (150 nM) for 30 min in culture medium at 37 °C and 5% CO2. As a positive control for Psi m loss, cells were incubated with 2 µM staurosporine for 2 h. Cells were washed once with phosphate-buffered saline, collected by centrifugation at 200 × g, and fixed in 2 ml of 4% paraformaldehyde in phosphate-buffered saline (pH 7.4) for 10 min at 4 °C. Fixed cells were analyzed by flow cytometry (BD PharMingen FACScan) using CellQuest acquisition software.

Preparation of Cytosolic Extracts-- Cells were collected by trypsinization and centrifuged at 200 × g for 5 min at 4 °C. Cells were then washed twice with ice-cold phosphate-buffered saline (pH 7.4), followed by an additional centrifugation at 200 × g for 5 min. The cell pellet was resuspended in 600 µl of extraction buffer containing 220 mM mannitol, 68 mM sucrose, 50 mM PIPES-KOH (pH 7.4), 50 mM KCl, 5 mM EGTA, 2 mM MgCl2, 1 mM dithiothreitol, and Complete protease inhibitor mixture. After 30 min of incubation on ice, cells were homogenized with a glass Dounce homogenizer and a small clearance pestle until the majority of the cells had been disrupted. Cell homogenates were spun at 14,000 × g for 15 min, and supernatants were removed and analyzed by Western blotting for cytochrome c.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

TIMP-3 Overexpression Induces Caspase Activation-- In agreement with previously published data (19, 21, 22), infection of rat VSMCs and HeLa cells with a replication-deficient adenovirus expressing human TIMP-3 (rAd/TIMP-3; 300 and 100 pfu/cell, respectively), but not with the control adenovirus (rAd/beta -galactosidase), induced apoptotic cell death 48-72 h post-infection (data not shown) (22, 30). TIMP-3-induced apoptosis was characterized by cell shrinkage, cell rounding, membrane blebbing, and cell detachment from the substratum. In situ end labeling staining of rAd/TIMP-3-infected cells revealed intense brown nuclear staining indicative of fragmented DNA, with nuclear condensation and fragmentation (data not shown). Cells expressing TIMP-3 also exhibited phosphatidylserine externalization as indicated by strong annexin V staining without uptake of propidium iodide (data not shown).

To characterize the intracellular downstream mechanism(s) activated by TIMP-3, we first measured the effect of TIMP-3 overexpression on caspase activity. Primary cultures of both rat VSMCs and HeLa cells infected with rAd/TIMP-3 exhibited increased effector caspase activity (50.1 ± 0.5- and 4.5 ± 0.2-fold (n = 3), respectively; p < 0.05) as measured by cleavage of the synthetic fluorescent substrate DEVD-7-amino-4-trifluoromethylcoumarin 72 h post-infection (Fig. 1A). Activation of initiator caspase-8 and -9 was also analyzed to identify possible mechanisms through which TIMP-3 initiates the apoptotic cascade. The activity of caspase-8 as measured by cleavage of IETD-7-amino-4-trifluoromethylcoumarin was elevated 18.61 ± 1.36- and 2.95 ± 0.36-fold (n = 3), respectively (p < 0.05) in rat VSMCs and HeLa cells, whereas cleavage of the caspase-9-specific substrate LEHD-7-amino-4-trifluoromethylcoumarin was elevated 10.88 ± 1.76- and 2.53 ± 0.35-fold (n = 3), respectively (p < 0.05) (Fig. 1A). Anti-activated caspase-8 and -9 antibodies also detected activated caspase-8 (p14) and caspase-9 (p37) in total HeLa cell lysates infected with rAd/TIMP-3, but not with rAd/beta -galactosidase (Fig. 1B). We performed a detailed time course experiment to evaluate caspase-8 and -9 cleavage following TIMP-3 overexpression. The activated fragments of caspase-8 and -9 were first detected 36 h post-infection and were both detected throughout the remaining time course of the experiment (Fig. 2A).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1.   TIMP-3 induces caspase activation. HeLa cells and rat VSMCs were infected with either the control adenovirus or rAd/TIMP-3 at 100 or 600 pfu/cell, respectively. A, cell lysates were prepared 72 h post-infection and analyzed for caspase activity using the quenched fluorescent substrates indicated. Data are presented as -fold induction of caspase activity detected in 2 × 106 cells. B, HeLa cell lysates were analyzed for active caspase-8 and -9 by Western blotting.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 2.   Time course of TIMP-3-induced caspase activation and death substrate cleavage. A, HeLa cells were infected with rAd/TIMP-3 (100 pfu/cell), and total cell lysates were prepared at the times indicated. Cell lysates (150 µg) were analyzed for activated caspase-8 and -9 and cleavage of PARP and FAK by Western blotting. B, cells infected with rAd/TIMP-3 were cultured in the presence of 100 µM benzyloxycarbonyl-VAD-fluoromethyl ketone (ZVAD) or 100 µM N-acetyl-Leu-Leu-norleucinal (ALLN). Cell lysates were prepared 72 h post-infection and analyzed for PARP and FAK cleavage by Western blotting.

Caspase-mediated cleavage of death substrates is an important event during the commitment to and execution of apoptotic death. Cleavage of PARP and FAK has previously been reported in numerous cell types undergoing apoptosis (32, 33). We therefore analyzed PARP and FAK cleavage status in TIMP-overexpressing cells. Infection of HeLa cells with rAd/TIMP-3 (but not with rAd/beta -galactosidase) resulted in the formation of two prominent lower molecular mass FAK fragments between 70 and 80 kDa and the appearance of an 85-kDa fragment of PARP detected with an anti-cleaved PARP antibody (Fig. 2A). Cleaved forms of FAK and PARP were first detectable 32-36 h after rAd/TIMP-3 infection and increased through the time course of the experiment (Fig. 2A). As expected, overexpression of TIMP-3 preceded the appearance of PARP and FAK cleavage by ~20 h (Fig. 2A). The time course of PARP and FAK cleavage mirrored that of initiator caspase-8 and -9 activation, suggesting that TIMP-3 induces caspase-mediated cleavage of FAK and PARP. To test this hypothesis, we incubated HeLa cells overexpressing TIMP-3 with either the pan-caspase inhibitor benzyloxycarbonyl-VAD-fluoromethyl ketone or the calpain peptide inhibitor N-acetyl-Leu-Leu-norleucinal. Incubation with benzyloxycarbonyl-VAD-fluoromethyl ketone (but not with N-acetyl-Leu-Leu-norleucinal) completely inhibited the formation of the lower molecular mass forms of FAK and the p85 PARP fragment, demonstrating caspase-mediated cleavage of these proteins in response to TIMP-3 overexpression (Fig. 2B).

TIMP-3 Induces Mitochondrial Activation-- Activation of the mitochondria and release of cytochrome c into the cytosol have been shown to participate in activation of caspase-9 (26). As we observed activation of caspase-9 in response to TIMP-3, we first measured changes in mitochondrial membrane potential (Delta Psi m) using CMTMRos and release of cytochrome c into the cytosol in rat VSMCs and HeLa cells infected with rAd/TIMP-3. rAd/beta -galactosidase-infected rat VSMCs and HeLa cells showed polarized Psi m as indicated by a high level of CMTMRos fluorescence (Fig. 3A). As expected, treatment with 2 µM staurosporine, a potent stimulus for mitochondrial activation, resulted in a marked reduction in CMTMRos fluorescence in both rat SMCs and HeLa cells, demonstrating a reduction in Psi m (Fig. 3A). Infection with rAd/TIMP-3 resulted in a similar reduction in Psi m (Fig. 3A). Interestingly, TIMP-3 overexpression resulted in a larger reduction in CMTMRos fluorescence than that evoked by staurosporine. To confirm these observations, efflux of cytochrome c into the cytosol, another indicator of mitochondrial activation, was evaluated (28, 34). Low levels of cytochrome c were detectable in cytosolic extracts from HeLa cells (but not from rat VSMCs) infected with the control virus rAd/beta -galactosidase (Fig. 3B). However, infection of both VSMCs and HeLa cells with rAd/TIMP-3 dramatically increased the levels of cytosolic cytochrome c (Fig. 3B).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3.   TIMP-3 induces mitochondrial activation. HeLa cells and rat VSMCs were infected with either the control adenovirus or rAd/TIMP-3 at 100 or 600 pfu/cell, respectively. A, 72 h post-infection, Delta Psi m was measured by CMTMRos staining and flow cytometry. The percentage of cells with low Psi m is seen as a shift to weaker CMTMRos fluorescence and was detected using CellQuest software. Uninfected cells were stimulated with 2 µM staurosporine for 2 h as a positive control. B, cytosolic extracts were analyzed for cytochrome c by Western blotting.

Bcl-2 and CrmA Block TIMP-3-induced Caspase Activation and Death Substrate Cleavage-- Numerous reports have described the role of Bcl-2 as a negative regulator of apoptosis-specific mitochondrial functions (reviewed in Refs. 35 and 36). The ratio between pro- and anti-apoptotic Bcl-2 family members is thought to regulate such functions as permeability transition pore formation and release of apoptosis inducing factor and cytochrome c into the cytosol and ultimately activation of caspase-9 (26). To determine whether mitochondrial activation is an important step in the apoptotic cascade initiated by TIMP-3, we used an adenoviral vector to up-regulate Bcl-2. Infection of HeLa cells with rAd/Bcl-2 (but not with rAd/beta -galactosidase) strongly elevated levels of Bcl-2 (Fig. 4A). For coexpression studies, we pretreated cells with rAd/Bcl-2 prior to rAd/TIMP-3 infection to allow sufficient inhibitor expression to precede expression of TIMP-3. Pre-infection with rAd/beta -galactosidase prior to co-infection with rAd/TIMP-3 failed to rescue cleavage of PARP and FAK (Fig. 4B). Pre-infection of HeLa cells with rAd/Bcl-2 prior to subsequent infection 3 h later with rAd/TIMP-3 blocked TIMP-3-induced cleavage of PARP and FAK death substrates (Fig. 4B). Additionally, overexpression of Bcl-2 inhibited activation of caspase-9, implying that the mitochondria function as regulators of caspase-9 activation in response to TIMP-3 (Fig. 4B). Furthermore, Bcl-2 co-overexpression also inhibited activation of caspase-8, suggesting that TIMP-3-induced caspase-8 activation occurs downstream of mitochondrial activation (Fig. 4B).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   Bcl-2 inhibits TIMP-3-induced apoptosis. A, HeLa cells were either left uninfected (first lane) or infected with the control adenovirus (rAd/beta -galactosidase (rAd:beta gal)) at 100 pfu/cell (second lane) or with rAd/Bcl-2 (third lane) as indicated. 72 h post-infection, total cell lysates were prepared and analyzed for Bcl-2 expression by Western blotting as indicated. B, HeLa cells were pre-infected with either the control adenovirus or rAd/Bcl-2 as described under "Methods" and then infected with either the control adenovirus or rAd/TIMP-3. 72 h post-infection, total cell lysates were prepared and analyzed for caspase-9 activation and cleaved PARP and FAK.

Although we have demonstrated activation of caspase-8 following adenovirus-mediated overexpression of TIMP-3, we further assessed the direct involvement of this caspase by co-overexpression of CrmA, a viral serpin inhibitor of caspase-8 (37), using adenovirus-mediated gene transfer. As expected, infection of HeLa cells with rAd/CrmA (but not with rAd/beta -galactosidase) resulted in high level expression of CrmA (Fig. 5A). Pre-infection of HeLa cells with rAd/CrmA (but not with rAd/beta -galactosidase) blocked cleavage of PARP and FAK induced by TIMP-3 and activation of caspase-8 (Fig. 5B). Furthermore, CrmA expression also inhibited activation of caspase-9 (Fig. 5B), implying that TIMP-3-induced caspase-9 activation occurs downstream of caspase-9.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 5.   CrmA inhibits TIMP-3-induced apoptosis. A, HeLa cells were either left uninfected (first lane) or infected with the control adenovirus (rAd/beta -galactosidase (rAd:beta gal)) at 100 pfu/cell (second lane) or with rAd/CrmA (third lane) as indicated. 72 h post-infection, total cell lysates were prepared and analyzed for CrmA expression by Western blotting as indicated. B, HeLa cells were pre-infected with either the control adenovirus or rAd/CrmA as described under "Methods" and then infected with either the control adenovirus or rAd/TIMP-3. 72 h post-infection, total cell lysates were prepared and analyzed for caspase-9 activation and cleaved PARP and FAK.

Dominant-negative FADD Blocks TIMP-3-induced Apoptosis-- Caspase-8 is typically activated in response to engagement of death receptors, which contain cytoplasmic death domains (38, 39). Caspase-8 is recruited to activated death receptors through interactions with the adaptor protein FADD, which contains a C-terminal death domain and an N-terminal death effector domain and which is responsible for recruitment and activation of caspase-8 (27). To test whether TIMP-3 induces death receptor-initiated apoptosis through caspase-8, we used an adenoviral vector expressing a death effector domain-deleted dominant-negative mutant of FADD (rAd/DN-FADD) (40). Infection of cells with rAd/DN-FADD resulted in high levels of DN-FADD expression (Fig. 6A) without affecting cell morphology and viability (Fig. 6D) or cleavage of PARP and FAK (Fig. 6, C and D). As expected, infection of HeLa cells with rAd/DN-FADD (but not with the control virus) completely blocked the cell detachment and membrane blebbing (Fig. 6D) and cleavage of PARP and FAK (Fig. 6B) induced by TNF-alpha , demonstrating that DN-FADD effectively inhibits apoptosis induced by death receptor engagement. Infection of HeLa cells with rAd/DN-FADD (but not with rAd/beta -galactosidase) not only prevented the morphological changes associated with TIMP-3-induced apoptosis (including cell shrinkage and detachment and membrane blebbing), but also completely blocked cleavage of PARP and FAK death substrates (Fig. 6, B and D). In addition, DN-FADD blocked both the basal and TIMP-3-induced apoptotic cell deaths as measured by a cell death nucleosome enzyme-linked immunosorbent assay (Fig. 6E), indicating that death receptor engagement is the initiating signal during TIMP-3-induced apoptosis.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 6.   DN-FADD inhibits TIMP-3-induced apoptosis. HeLa cells were pre-infected with the control adenovirus (rAd/beta -galactosidase (rAd:beta gal)) or rAd/DN-FADD. A, expression of DN-FADD protein was measured by Western blotting. Cells were stimulated with 50 ng/ml TNF-alpha for 6 h and analyzed for cleavage of PARP and FAK by Western blotting (B) or infected with the control adenovirus or rAd/TIMP-3 and analyzed for cleavage of PARP and FAK by Western blotting (C). D, cell morphology was analyzed by phase contrast microscopy. E, cell death was also analyzed by nucleosome enzyme-linked immunosorbent assay.

Analysis of Candidate Receptors-- To define the death receptor(s) responsible for the transmission of the apoptotic stimuli, we investigated the expression of known death receptors in response to TIMP-3 overexpression. It has been hypothesized that stabilization of TNF-alpha receptors on the cell surface of colon cancer cells is involved in the apoptotic cascade initiated by TIMP-3 (23). Additionally, TIMP-3 is a potent inhibitor of TNF-alpha -converting enzyme, a cell-surface metalloprotease involved in the processing of cell-surface TNF-alpha (2). Consistent with this, infection of VSMCs or HeLa cells with rAd/TIMP-3 (but not with rAd/beta -galactosidase) resulted in increased cell-surface levels of TNF-alpha (Fig. 7A), presumably through inhibition of TNF-alpha -converting enzyme-mediated TNF-alpha shedding from the cell surface. To test whether this increase in cell-surface TNF-alpha is responsible for TIMP-3-induced apoptosis, we used an antibody that neutralizes the biological actions of TNF-alpha . As expected, cleavage of PARP and FAK death substrates in response to recombinant TNF-alpha was almost completely blocked by co-incubation with 5 µg/ml TNF-alpha -neutralizing antibody (Fig. 7B), demonstrating the efficacy of the antibody. However, incubation with the TNF-alpha -neutralizing antibody had no effect on TIMP-3-induced death substrate cleavage, indicating that TIMP-3-induced apoptosis occurs independently of TNF-alpha (Fig. 7B). Furthermore, co-incubation with recombinant soluble Fas/Fc or soluble TRAIL receptor also had no effect on TIMP-3-induced apoptosis (data not shown).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 7.   TIMP-3-induced TNF-alpha -independent apoptosis. A, HeLa cells and VSMCs were infected with rAd/beta -galactosidase (rAd:beta gal) and rAd/TIMP-3 and analyzed for cell-surface TNF-alpha by two-step immunofluorescent staining and flow cytometry 48 h post-infection. B, apoptosis was induced in HeLa cells by infection with rAd/TIMP-3 or treatment with 50 ng/ml TNF-alpha and 2 µg/ml cycloheximide. Cells were simultaneously treated with 5 µg/ml TNF-alpha -neutralizing antibody (Anti-TNF-alpha N/A) and analyzed for induction of apoptosis by Western blotting of cleavage of PARP and FAK death substrates 72 h after rAd/TIMP-3 infection or 6 h after TNF-alpha treatment.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Imbalances between the levels of TIMPs and MMPs have been implicated in the pathogenesis of many diseases such as rheumatoid arthritis, tumor cell invasion and metastasis, atherosclerosis, and fibrosis. Although imbalances in net proteolytic activity are a major factor in the progression of these diseases, the additional functions of TIMPs, including the regulation of apoptosis, are also likely to be important. The processes regulating cell death are complex and involve intricate interplay between the extracellular microenvironment, the cell membrane, and intracellular organelles. MMPs, ADAMs, and their endogenous inhibitors (TIMPs) are attracting increasing attention as mediators of apoptotic stimuli through mechanisms including control of matrix remodeling and anoikis and via regulation of death ligands and their receptors at the cell surface.

Although there is no direct evidence in the literature for regulation of apoptosis by physiological levels of TIMP-3, there are ample data to suggest that dysregulation of TIMP-3 levels, either through increased endogenous expression or ectopic overexpression or through knockout, leads to direct effects on apoptotic cell death. For example, endogenous TIMP-3 levels are high in shoulder regions of advanced atherosclerotic plaques, the regions at which increased apoptosis of VSMCs leads to plaque destabilization and rupture (42-44). More direct evidence is observed in the rare inherited disorder Sorsby's fundus dystrophy, a degenerative disease of the retina characterized by thickening of the Bruch's membrane and apoptotic death of the retinal epithelial pigment cells (45-47). In Sorsby's fundus dystrophy, mutations in the coding region of TIMP-3, which, interestingly, all lead to an alteration in the number of cysteine residues, have been identified (45, 46), although a direct link between altered TIMP-3 activity and/or distribution has not been documented. Induction of apoptotic cell death by TIMP-3 overexpression is well documented and has been shown in vascular cells and cancer cells in vitro and in vivo (19, 23, 30, 48). Beneficial effects of TIMP-3 in these scenarios include modulation of both cell migration and invasion through MMP blockade, reduced angiogenesis, and elevated rates of apoptosis, the latter through unknown mechanisms. Smith et al. (23) have reported that TIMP-3 induces apoptosis of DLD carcinoma cells via stabilization of cell-surface TNF-alpha receptors. Interestingly, recent evidence has demonstrated, at least in the mouse, that the absence of TIMP-3 leads to apoptotic cell death in involuting breast tissue (24). There is therefore an increasing need to understand the precise mechanism(s) that TIMP-3 regulates during physiological processes as well as the signaling pathways activated through TIMP-3 overexpression. The latter is especially important for the potential exploitation of TIMP-3 as an effective gene-based pro-death therapy for vascular disease (21) and cancer (48, 49). Modulation of apoptosis by other metalloproteinase inhibitors has been described (50-52). Mitsiades et al. (53) have described the induction of Fas-mediated apoptosis in Ewing's sarcoma cell lines by synthetic metalloproteinase inhibitors. Additionally, TIMP-4 has recently been shown to promote apoptosis of transformed cardiac fibroblasts (54).

A large body of evidence demonstrates the major role played by the caspases in the execution of apoptotic cell death in response to numerous signals (55). The caspase cascade can be activated via the activity of two families of initiator caspases. Members of the caspase-8 family are typically recruited to activated death receptors via interactions with adaptor proteins such as FADD, where they form part of the death-inducing signaling complex (27). The caspase-9 family (caspase-9 and -2) is thought to be important in activating the downstream effector caspases in response to signals generated by the mitochondria (25, 26). Caspase-9 activation requires the formation of a cytosolic complex with APAF, ATP, and cytochrome c released from the mitochondria (26). Here we have demonstrated that TIMP-3 increased caspase activity and caspase-mediated cleavage of the death substrates FAK and PARP. Depolarization of the mitochondrial membrane and release of cytochrome c also suggest that the mitochondria play an important role in regulating apoptosis induced by TIMP-3. Interestingly, TIMP-3 induced activation of both initiator caspase-8 and -9, suggesting that these caspases may play a role in the initiation of apoptosis by TIMP-3. To identify the initiating signal and the apical caspase activated by TIMP-3, we employed recombinant adenoviral vectors expressing Bcl-2, a negative regulator of apoptosis-specific mitochondrial functions (56, 57); CrmA, a cowpox serpin inhibitor of caspase-8; and DN-FADD, a death receptor adaptor protein involved in activation of caspase-8 (27). Overexpression of Bcl-2 completely inhibited activation of caspase-9, demonstrating that mitochondrial activation is responsible for activation of caspase-9 during TIMP-3-induced apoptosis. TIMP-3 overexpression also resulted in a drop in mitochondrial membrane potential and a release of cytochrome c into the cytosol. The importance of this mitochondrial activation in the progression of TIMP-3-induced apoptosis is demonstrated by the complete inhibition of death substrate cleavage by overexpression of Bcl-2. Expression of Bcl-2 also inhibited activation of caspase-8, suggesting that the majority of caspase-8 activation in response to TIMP-3 occurs downstream of mitochondrial activation. Inhibition of caspase-8 activation by Bcl-2 has been described previously in Jurkat cells that undergo a type II apoptotic pathway in response to the Fas ligand (28). In cells that undergo a type II apoptotic pathway, death receptor engagement initially triggers only a small amount of caspase-8 activation, leading to activation of the mitochondria, which in turn results in cleavage of caspase-9, downstream effector caspases such as caspase-3, and ultimately more caspase-8. In this type of pathway, caspase-8 is the apical caspase, and the mitochondria function as amplifiers of the caspase cascade. To test whether TIMP-3 induces a similar type II apoptotic mechanism in HeLa cells, we used an adenovirus carrying CrmA. Infection of HeLa cells with rAd/CrmA (but not the control virus) inhibited TIMP-3-induced activation of caspase-9 and cleavage of FAK and PARP death substrates. These data are consistent with the hypothesis that TIMP-3 induces a type II apoptotic pathway initiated by caspase-8.

Taken together, the data suggest that TIMP-3 induces apoptosis via a death receptor-mediated mechanism. To confirm this, we used a dominant-negative mutant of FADD, a protein involved in recruitment of caspase-8 to the death-inducing signaling complex, where it is subsequently activated. Apoptosis induced by death ligands such as TNF-alpha and Fas ligand have previously been shown to be blocked by overexpression of DN-FADD mutants that are unable to recruit caspase-8 (58-60). We have shown that infection of HeLa cells with rAd/DN-FADD completely blocked TNF-alpha -induced cleavage of FAK and PARP. Furthermore, expression of DN-FADD also completely inhibited TIMP-3-induced cleavage of FAK and PARP and the morphological changes associated with apoptosis such as membrane blebbing and cell detachment, demonstrating that TIMP-3 induces FADD-dependent apoptosis. Taken together, these data strongly suggest that TIMP-3 initiates a type II apoptotic pathway via a FADD-sensitive death receptor.

Clearly, the identity of the death receptor that mediates TIMP-3-induced apoptosis is of great interest. Previous studies have suggested that TNF receptor-1 plays a role in TIMP-3-induced apoptosis of DLD carcinoma cells (23). Here we have reported that TIMP-3 overexpression resulted in increased levels of cell-surface TNF-alpha in both VSMCs and HeLa cells. However, neutralization of this TNF-alpha had no effect on TIMP-3-induced apoptosis. This probably reflects differences in death receptor and death ligand expression. Furthermore, incubation with recombinant soluble Fas/Fc and soluble TRAIL receptors, which inhibit Fas ligand- and TRAIL-mediated apoptosis by acting as decoy receptors (41), also failed to block TIMP-3-induced apoptosis. These data demonstrate that TIMP-3-induced apoptosis in HeLa cells and VSMCs occurs independently of TNF-alpha , Fas ligand, or TRAIL. However, this does not rule out the possibility of ligand-independent actions of TNF receptor-1 or Fas or TRAIL receptors.

In summary, this study has highlighted the involvement of a FADD-dependent type II apoptotic pathway in the induction of apoptosis by TIMP-3. These findings are likely to have important implications for our understanding of the normal physiological roles of TIMP-3, the involvement of TIMP-3 in diseases such as Sorsby's fundus dystrophy, and the future development of TIMP-3-based gene therapies.

    ACKNOWLEDGEMENT

We thank Dr. J. Boyle (Department of Medicine, Addenbrooke's Hospital, University of Cambridge) for help with the flow cytometric analysis of cell-surface TNF-alpha .

    FOOTNOTES

* This work was supported in part by the British Heart Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed. Tel.: 44-117-9283154; Fax: 44-117-9283581; E-mail: Mark.bond@bris.ac.uk.

|| Supported by the Wellcome Trust and the Medical Research Council.

Published, JBC Papers in Press, February 4, 2002, DOI 10.1074/jbc.M111507200

    ABBREVIATIONS

The abbreviations used are: TIMPs, tissue inhibitors of metalloproteinases; MMP, matrix metalloproteinase; TNF, tumor necrosis factor; FADD, Fas-associated death domain; VSMCs, vascular smooth muscle cells; SMCs, smooth muscle cells; PARP, poly(ADP-ribose) polymerase; FAK, focal adhesion kinase; rAd, recombinant adenovirus; DN, dominant-negative; pfu, plaque-forming units; PIPES, 1,4-piperazinediethanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Birkedal-Hansen, H., Moore, W. G. I., Bodden, M. K., Windsor, L. J., Birkedal-Hansen, B., De, Carlo, A., and Engler, J. A. (1993) Crit. Rev. Oral Biol. Med. 4, 197-250[Abstract/Free Full Text]
2. Amour, A., Slocombe, P. M., Webster, A., Butler, M., Knight, C. G., Smith, B. J., Stephens, P. E., Shelley, C., Hutton, M., Knauper, V., Docherty, A. J. P., and Murphy, G. (1998) FEBS Lett. 435, 39-44[CrossRef][Medline] [Order article via Infotrieve]
3. Docherty, A. J. P., Lyons, A., Smith, B. J., Wright, E. M., Stephens, P. E., Harris, T. J. R., Murphy, G., and Reynolds, J. J. (1985) Nature 318, 66-69[CrossRef][Medline] [Order article via Infotrieve]
4. Apte, S. S., Mattei, M. G., and Olsen, B. R. (1994) Genomics 19, 86-90[CrossRef][Medline] [Order article via Infotrieve]
5. Boone, T. C., Johnson, M. J., DeClerck, Y. A., and Langley, K. E. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2800-2804[Abstract/Free Full Text]
6. Greene, J., Wang, M. S., Liu, Y. L. E., Raymond, L. A., Rosen, C., and Shi, Y. N. E. (1996) J. Biol. Chem. 271, 30375-30380[Abstract/Free Full Text]
7. Gomez, D. E., Alonso, D. F., Yoshiji, H., and Thorgeirsson, U. P. (1997) Eur. J. Cell Biol. 74, 111-122[Medline] [Order article via Infotrieve]
8. Langton, K. P., Barker, M. D., and McKie, N. (1998) J. Biol. Chem. 273, 16778-16781[Abstract/Free Full Text]
9. Yu, W. H., Brew, K., Yu, S. S., Meng, Q., and Woessner, F. (1998) Mol. Biol. Cell 9, 1024
10. Leco, K. J., Khokha, R., Pavloff, N., Hawkes, S. P., and Edwards, D. R. (1994) J. Biol. Chem. 269, 9352-9360[Abstract/Free Full Text]
11. Goldberg, G. I., Marmer, B. L., Grant, G. A., Eisen, A. Z., Wilhelm, S., and He, C. S. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 8207-8211[Abstract/Free Full Text]
12. Wilhelm, S. M., Collier, I. E., Marmer, B. L., Eisen, A. Z., Grant, G. A., and Goldberg, G. I. (1989) J. Biol. Chem. 264, 17213-17221[Abstract/Free Full Text]
13. Stetler-Stevenson, W. G., Krutzsch, H. C., and Liotta, L. A. (1989) J. Biol. Chem. 264, 17374-17378[Abstract/Free Full Text]
14. Takigawa, M., Nishida, Y., Suzuki, F., Kishi, J., Yamashita, K., and Hayakawa, T. (1990) Biochem. Biophys. Res. Commun. 171, 1264-1271[CrossRef][Medline] [Order article via Infotrieve]
15. Stetler-Stevenson, W. G., Bersch, N., and Golde, D. W. (1992) FEBS Lett. 296, 231-234[CrossRef][Medline] [Order article via Infotrieve]
16. Strongin, A., Collier, I. E., Bannikov, G., Marmer, B., Grant, G., and Goldberg, G. (1995) J. Biol. Chem. 270, 5331-5338[Abstract/Free Full Text]
17. Corcoran, M. L., and Stetler-Stevenson, W. G. (1995) J. Biol. Chem. 270, 13453-13459[Abstract/Free Full Text]
18. Hayakawa, T., Yamashita, K., Ohuchi, E., and Shinagawa, A. (1994) J. Cell Sci. 107, 2373-2379[Abstract]
19. Baker, A. H., George, S. J., Zaltsman, A. B., Murphy, G., and Newby, A. C. (1999) Br. J. Cancer 79, 1347-1355[CrossRef][Medline] [Order article via Infotrieve]
20. Ahonen, M., Baker, A. H., and Kahari, V. M. (1998) Cancer Res. 58, 2310-2315[Abstract/Free Full Text]
21. George, S. J., Lloyd, C. T., Angelini, G. D., Newby, A. C., and Baker, A. H. (2000) Circulation 101, 296-304[Abstract/Free Full Text]
22. Bond, M., Murphy, G., Bennett, M., Amour, A., Knauper, V., and Newby, A. C. (2000) J. Biol. Chem. 275, 41358-41363[Abstract/Free Full Text]
23. Smith, M. R., Kung, H. F., Durum, S. K., Colburn, N. H., and Sun, Y. (1997) Cytokine 9, 770-780[CrossRef][Medline] [Order article via Infotrieve]
24. Fata, J. E., Leco, K. J., Voura, E. B., Yu, H. Y. E., Waterhouse, P., Murphy, G., Moorehead, R. A., and Khokha, R. (2001) J. Clin. Invest. 108, 831-841[CrossRef][Medline] [Order article via Infotrieve]
25. Budihardjo, I., Oliver, H., Lutter, M., Luo, X., and Wang, X. D. (1999) Annu. Rev. Cell Dev. Biol. 15, 269-290[CrossRef][Medline] [Order article via Infotrieve]
26. Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. D. (1997) Cell 91, 479-489[CrossRef][Medline] [Order article via Infotrieve]
27. Ashkenazi, A., and Dixit, V. (1998) Science 277, 1305-1308
28. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K., Krammer, P. H., and Peter, M. E. (1998) EMBO J. 17, 1675-1687[CrossRef][Medline] [Order article via Infotrieve]
29. Bennett, M. R., Anglin, S., McEwan, J. R., Jagoe, R., Newby, A. C., and Evan, G. I. (1994) J. Clin. Invest. 93, 820-828[Medline] [Order article via Infotrieve]
30. Baker, A. H., Zaltsman, A. B., George, S. J., and Newby, A. C. (1998) J. Clin. Invest. 101, 1478-1487[Medline] [Order article via Infotrieve]
31. Macho, A., Decaudin, D., Castedo, M., Hirsch, T., Susin, S., Zamzami, N., and Kroemer, G. (1996) Cytometry 25, 333-340[CrossRef][Medline] [Order article via Infotrieve]
32. Margolin, N., Raybuck, S. A., Wilson, K. P., Chen, W., Fox, T., Gu, Y., and Livingston, D. J. (1997) J. Biol. Chem. 272, 7223-7228[Abstract/Free Full Text]
33. Levkau, B., Herren, B., Koyama, H., Ross, R., and Raines, E. W. (1998) J. Exp. Med. 187, 579-586[Abstract/Free Full Text]
34. Yang, J., Liu, X. S., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J. Y., Peng, T. I., Jones, D. P., and Wang, X. D. (1997) Science 275, 1129-1132[Abstract/Free Full Text]
35. Adams, J. M., and Cory, S. (2001) Trends Biochem. Sci. 26, 61-66[CrossRef][Medline] [Order article via Infotrieve]
36. Antonsson, B., and Martinou, J. C. (2000) Exp. Cell Res. 256, 50-57[CrossRef][Medline] [Order article via Infotrieve]
37. Bennett, M., Macdonald, K., Chan, S. W., Luzio, J. P., Simari, R., and Weissberg, P. (1998) Science 282, 290-293[Abstract/Free Full Text]
38. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. (1996) Cell 85, 817-827[CrossRef][Medline] [Order article via Infotrieve]
39. Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., Litwack, G., and Alnemri, E. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 14486-14491[Abstract/Free Full Text]
40. Bradham, C., Qian, T., Streetz, K., Trautwein, C., Brenner, D., and Lemasters, J. (1998) Mol. Cell. Biol. 18, 6353-6364[Abstract/Free Full Text]
41. Rytomaa, M., Martins, L., and Downward, J. (1999) Curr. Biol. 9, 1043-1046[CrossRef][Medline] [Order article via Infotrieve]
42. Fabunmi, R. P., Sukhova, G. K., Sugiyama, S., and Libby, P. (1998) Circ. Res. 83, 270-278[Abstract/Free Full Text]
43. Geng, Y. J., and Libby, P. (1995) Circulation 92, 471-471
44. Bjorkerud, S., and Bjorkerud, B. (1996) Am. J. Pathol. 149, 367-380[Abstract]
45. Weber, B. H. F., Vogt, G., Pruett, R. C., Stohr, H., and Felbor, U. (1994) Nat. Genet. 8, 352-356[CrossRef][Medline] [Order article via Infotrieve]
46. AnandApte, B., Bao, L., Smith, R., Iwata, K., Olsen, B. R., Zetter, B., and Apte, S. S. (1996) Biochem. Cell Biol. 74, 853-862[Medline] [Order article via Infotrieve]
47. Majid, M., Smith, V. A., Easty, D., and Baker, A. (2001) Br. J. Ophthalmol., in press
48. Ahonen, M., Baker, A. H., and Kahari, V. M. (1998) Cancer Res. 58, 2310-2315[Abstract/Free Full Text]
49. Ahonen, M. A., Baker, A. H., George, S. J., Saarialho-Kere, U., and Kahari, V. M. (2000) J. Invest. Dermatol. 115, 575
50. Guedez, L., Courtmanch, L., and Stetler-Stevenson, M. (1998) Blood 92, 1342-1349[Abstract/Free Full Text] W. G.
51. Guedez, L., Stetler-Stevenson, W. G., Wolff, L., Wang, J., Fukushima, P., Mansoor, A., and Stetler-Stevenson, M. (1998) J. Clin. Invest. 102, 2002-2010[Medline] [Order article via Infotrieve]
52. Gaudin, P., Trocme, C., Berthier, S., Kieffer, S., Boutonnat, J., Lamy, C., Surla, A., Garin, J., and Morel, F. (2000) Biochim. Biophys. Acta 1499, 19-33[Medline] [Order article via Infotrieve]
53. Mitsiades, N., Poulaki, V., Leone, A., and Tsokos, M. (1999) J. Natl. Cancer Inst. 91, 1678-1684[Abstract/Free Full Text]
54. Tummalapalli, C. M., Heath, B. J., and Tyagi, S. C. (2001) J. Cell. Biochem. 80, 512-521[CrossRef][Medline] [Order article via Infotrieve]
55. Chang, H. Y., and Yang, X. L. (2000) Microbiol. Mol. Biol. Rev. 64, 821[Abstract/Free Full Text]
56. Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R., and Korsmeyer, S. (1990) Nature 348, 334-336[CrossRef][Medline] [Order article via Infotrieve]
57. Reed, J. (1994) J. Cell Biol. 124, 1-6[Free Full Text]
58. Chinnaiyan, A. M., Tepper, C. G., Seldin, M. F., O'Rourke, K., Kischkel, F. C., Hellbardt, S., Krammer, P. H., Peter, M. E., and Dixit, V. M. (1996) J. Biol. Chem. 271, 4961-4965[Abstract/Free Full Text]
59. Wajant, H., Johannes, F. J., Haas, E., Siemienski, K., Schwenzer, R., Schubert, G., Weiss, T., Grell, M., and Scheurich, P. (1997) Curr. Biol. 8, 113-116
60. Schneider, P., Thome, M., Burns, K., Bodmer, J. L., Hofmann, K., Kataoka, T., Holler, N., and Tschopp, J. (1997) Immunity 7, 831-836[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
C. Chetty, S. S. Lakka, P. Bhoopathi, S. Kunigal, R. Geiss, and J. S. Rao
Tissue Inhibitor of Metalloproteinase 3 Suppresses Tumor Angiogenesis in Matrix Metalloproteinase 2-Down-regulated Lung Cancer
Cancer Res., June 15, 2008; 68(12): 4736 - 4745.
[Abstract] [Full Text] [PDF]